

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

Drug Safety

Mats Carlsson,¹ Martin Braddock,² Yuling Li,³ Jihong Wang,³ Weichen Xu,³ Nicholas White,⁴ Ayman Megally,⁵ Gillian Hunter,⁶ Gene Colice⁵

¹Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, Mölndal, SE-431 83, Sweden

²Global Medicines Development, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

³Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, Maryland 20878, United States

⁴Clinical Pharmacology, Pharmacometrics and DMPK, MedImmune, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

⁵Global Medicines Development, AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United States

⁶Biometrics and Information Sciences, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

Corresponding author: Mats Carlsson, Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, Mölndal, SE-431 83, Sweden.

Mats.Carlsson@astrazeneca.com

Electronic Supplementary Material 4

Lys-C disulphide bond mapping to confirm disulphide bonds of tralokinumab. *H* heavy chain peptide, *L* light chain peptide. ^aReagent peak. ^bpeptide from Lys-C enzyme autolysis

